ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,57
0,91%
Dow Jones
38 626,22
0,10%
DAX
18 068,21
0,26%
Brent Oil
83,115
1,21%
Bitcoin
65 492,25
-1,72%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) Actualités

PRLD Prelude Therapeutics Inc

3,85
-0,04 (-1,03%)
Dernière mise à jour : 17:48:26
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Prelude Therapeutics Inc PRLD NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,04 -1,03% 3,85 17:48:26
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,88 3,7222 3,95 3,89
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
12/6/202412:55EDGAR2Form 8-K - Current report
11/6/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
03/6/202413:01GLOBEPrelude Therapeutics to Participate in Upcoming Healthcare..
30/5/202422:29EDGAR2Form S-3 - Registration statement under Securities Act of..
16/5/202422:09EDGAR2Form 8-K/A - Current report: [Amend]
16/5/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202413:01GLOBEPrelude Therapeutics to Participate in Citizens JMP Life..
07/5/202413:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:12EDGAR2Form 8-K - Current report
07/5/202413:01GLOBEPrelude Therapeutics Reports First Quarter 2024 Financial..
06/5/202422:24EDGAR2Form S-3/A - Registration statement under Securities Act of..
09/4/202422:35GLOBEPrelude Highlights Continued Strength of Discovery Engine at..
05/3/202422:45GLOBEPrelude Announces Acceptance of Multiple Preclinical..
05/3/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:05GLOBEPrelude Therapeutics to Participate in Barclays Global..
15/2/202423:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202422:22EDGAR2Form 8-K - Current report
15/2/202422:05GLOBEPrelude Therapeutics Reports Full Year 2023 Financial..
12/2/202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:34GLOBEPrelude Therapeutics Announces $25 Million Private Placement
11/12/202315:17EDGAR2Form 8-K - Current report
01/11/202321:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202321:23EDGAR2Form 8-K - Current report
01/11/202321:10GLOBEPrelude Announces Strategic Pipeline Progress and Updates,..
01/11/202321:05GLOBEPrelude Therapeutics and AbCellera Enter Partnership to..
14/10/202318:30GLOBEPrelude Announces Multiple Clinical and Preclinical Poster..
06/10/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202314:30GLOBEPrelude Therapeutics to Participate in Three Healthcare..
03/8/202314:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202314:10EDGAR2Form 8-K - Current report
03/8/202314:00GLOBEPrelude Therapeutics Announces Second Quarter 2023 Financial..
06/7/202322:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
PRLD
Prelude Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés